[CAS NO. 2349294-95-5] Tusamitamab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2349294-95-5]

Catalog

AS1027200

Brand

Arctom Scientific

CAS

2349294-95-5

DESCRIPTION [2349294-95-5]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Tusamitamab]

For research use only. We do not sell to patients.

Summary

Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5 . Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative) ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04154956	Sanofi	Non-small Cell Lung Cancer Metastatic	February 6, 2020	Phase 3
NCT04659603	Sanofi	Breast Cancer Metastatic\|Pancreatic Carcinoma Metastatic	March 29, 2021	Phase 2
NCT05071053	Sanofi	Adenocarcinoma Gastric\|Gastrooesophageal Cancer	November 16, 2021	Phase 2
NCT05429762	Sanofi	Neoplasm	October 3, 2022	Phase 1
NCT05245071	Sanofi	Non-squamous Non-small Cell Lung Cancer	June 3, 2022	Phase 2

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Clemence Pouzin, et al. Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study. CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):384-394.